Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
NEW YORK, June 19, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-03831) against Zoompass Holdings, Inc. (“Zoompass” or the “Company”)(OTC:ZPAS) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 (the “Exchange Act”) and is brought on behalf of a class consisting of all persons or entities that acquired Zoompass securities between April 24, 2017 and May 24, 2017, inclusive (the “Class Period”). If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke ([email protected]) or Jonathan Dilger ([email protected]); (866) 540-5505.
The Complaint alleges that, throughout the Class Period, Zoompass made false and/or misleading statements and/or failed to disclose that: (1) the Company engaged in a scheme to illegally promote its stock; (2) the foregoing conduct, when discovered, would expose the Company to heightened regulatory scrutiny and possible criminal sanctions; and (3) as a result of the foregoing, Zoompass’ public statements were materially false and misleading at all relevant times.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Zoompass securities during the Class Period, we encourage you to contact us with any questions prior to the July 31, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England and Milan, Italy. SFMS has recovered hundreds of millions of dollars on behalf of investors. For more information visit us at http://www.sfmslaw.com.
Contacts: Bruce Parke Jonathan Dilger Shepherd Finkelman Miller & Shah, LLP www.sfmslaw.com Telephone: (866) 540-5504 Email: [email protected] [email protected]
